117 related articles for article (PubMed ID: 36222123)
1. Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer.
Hong J; Guo G; Wu S; Lin S; Zhou Z; Chen S; Ye C; Li J; Lin W; Ye Y
J Leukoc Biol; 2022 Dec; 112(6):1577-1590. PubMed ID: 36222123
[TBL] [Abstract][Full Text] [Related]
2. An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer.
Yu H; Ye C; Li J; Pan C; Lin W; Chen H; Zhou Z; Ye Y
Exp Cell Res; 2020 May; 390(1):111953. PubMed ID: 32156601
[TBL] [Abstract][Full Text] [Related]
3. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
6. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
[TBL] [Abstract][Full Text] [Related]
7. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
Stepensky D; Tzehoval E; Vadai E; Eisenbach L
Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
[TBL] [Abstract][Full Text] [Related]
8. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
9. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
Brossart P; Heinrich KS; Stuhler G; Behnke L; Reichardt VL; Stevanovic S; Muhm A; Rammensee HG; Kanz L; Brugger W
Blood; 1999 Jun; 93(12):4309-17. PubMed ID: 10361129
[TBL] [Abstract][Full Text] [Related]
10. Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.
Chen J; Li HY; Wang D; Zhao JJ; Guo XZ
J Gastroenterol Hepatol; 2011 Oct; 26(10):1509-18. PubMed ID: 21950745
[TBL] [Abstract][Full Text] [Related]
11. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.
Pathangey LB; Lakshminarayanan V; Suman VJ; Pockaj BA; Mukherjee P; Gendler SJ
Biomolecules; 2016 Jun; 6(3):. PubMed ID: 27367740
[TBL] [Abstract][Full Text] [Related]
13. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
[TBL] [Abstract][Full Text] [Related]
15. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
[TBL] [Abstract][Full Text] [Related]
16. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tomita Y; Tsunoda T; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Br J Cancer; 2011 Jan; 104(2):300-7. PubMed ID: 21179034
[TBL] [Abstract][Full Text] [Related]
17. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope.
Heukamp LC; van Hall T; Ossendorp F; Burchell JM; Melief CJ; Taylor-Papadimitriou J; Offringa R
J Immunother; 2002; 25(1):46-56. PubMed ID: 11926165
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer.
Lee HJ; Hong CY; Jin CJ; Kim MH; Lee YK; Nguyen-Pham TN; Lee H; Park BC; Chung IJ; Kim HJ; Lee JJ
Cell Mol Immunol; 2012 Mar; 9(2):175-83. PubMed ID: 22231555
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy for unresectable pancreatic cancer].
Yahara N; Oka M
Gan To Kagaku Ryoho; 2002 Mar; 29(3):390-7. PubMed ID: 11915728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
